Senseonics and Rimidi Collaborate on New Diabetes Solution

Senseonics Holdings, Inc., a company specializing in the development of long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management, has announced a new strategic partnership with Rimidi. Rimidi offers a clinical management platform aimed at optimizing clinical workflows, enhancing patient experiences, and meeting chronic disease management goals. This partnership is set to enhance the Eversense® Remote Patient Monitoring (RPM) Program, targeting healthcare providers who manage patients with diabetes.

The collaboration will merge Eversense glucose data into Rimidi's clinical management platform, which is already in use by various health systems and physician practices. Rimidi’s platform aligns with Medicare’s reimbursable remote patient monitoring telehealth programs. It integrates smoothly with existing Electronic Health Record (EHR) systems, thereby supporting quality improvement initiatives, optimizing workflows, increasing patient engagement, and offering clinical decision support.

Rimidi's CEO, Lucienne Ide, MD, PhD, emphasized the potential of this partnership to significantly impact diabetes management. She highlighted that a substantial number of patients with type 2 diabetes fail to meet their HbA1c, blood pressure, and cholesterol goals. The integration of Eversense CGM data into Rimidi's platform aims to assist healthcare providers in improving glucose outcomes for these patients.

The Eversense CGM + RPM solution, powered by Rimidi, promises to securely push patient glucose data to widely used EHR systems. This integration will offer healthcare providers direct access to glucose trends, high or low event frequency, and time-in-range statistics. Consequently, providers can proactively engage with patients to offer lifestyle and therapy optimization guidance, thereby improving diabetes management, reducing healthcare costs, and enhancing clinical outcomes.

Tim Goodnow, PhD, President and CEO of Senseonics, expressed enthusiasm about the Eversense RPM Program. He noted that this initiative is a crucial step in combining long-term implantable CGM technology with advanced analytics and personalized health services into a comprehensive diabetes solution. Goodnow highlighted that the Eversense RPM will equip providers with critical data to optimize care between office visits, where the majority of diabetes management occurs.

The partnership with Rimidi aims to seamlessly integrate Eversense data, augmented by expert diabetes nurse counselors, proprietary decision support protocols, and a fully compliant RPM reimbursement infrastructure. This comprehensive approach is intended to set Eversense apart from other CGM manufacturers, offering a holistic solution for healthcare systems, providers, and patients. Senseonics is confident that this program will align with Medicare’s diabetes population management initiatives, providing healthcare professionals with the assurance that patients have support outside of their office visits, and giving patients the confidence to achieve healthy outcomes.

In collaboration with its commercial partner, Ascensia Diabetes Care, Senseonics plans to introduce the Eversense CGM+RPM solution to select population health-based systems by the third quarter of 2024. The program is expected to expand to all healthcare prescribers and users of Eversense subsequently.

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is designed for continuous glucose measurement for up to 180 days in individuals aged 18 and older with diabetes. It replaces fingerstick blood glucose measurements for diabetes treatment decisions, although fingerstick measurements are still required for calibration primarily after day 21 or when symptoms do not match CGM information.

Senseonics Holdings, Inc. is committed to transforming lives in the diabetes community through their innovative glucose monitoring technology, underlined by the Eversense CGM system. This system includes a small sensor implanted under the skin, communicating with a smart transmitter worn on the skin, and sending glucose data every five minutes to a mobile app.

Rimidi, a digital health company established by doctors, supports healthcare providers in delivering remote patient monitoring and chronic disease management. Their platform integrates EHR data with data from connected devices and patient surveys to present a complete picture of the patient, facilitating proactive, guideline-based management.